profit from every $100 of sales.
$0$100
Tonix Pharmaceuticals
$4.49-5.27% today
-73.6% in 1 year
1-year low $4.491-year high $19.89
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Tonix Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $13.1 million in 2025, with -$124 million of profit last year.
SalesProfit
Tonix Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tonix Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Tonix Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 8 | 10 | 13 | |
| 0 | 3 | 2 | 6 | |
| -112 | -118 | -75 | -123 | |
| -111 | -114 | -125 | -122 | |
| -110 | -117 | -130 | -124 | |
| -65,400.00 | -14,720.25 | -176.60 | -14.57 | |
| – | 39.0% | 23.1% | 49.3% | |
| – | -1,523.9% | -744.5% | -936.1% | |
| – | -1,501.8% | -1,288.3% | -946.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 226 | 154 | 163 | 277 |
| Cash | 120 | 25 | 99 | 208 |
| Total debt | 1 | 10 | 8 | 1 |
| Total liabilities | 19 | 49 | 23 | 32 |
| 207 | 106 | 140 | 245 | |
| 0 | 0 | 1 | 9 | |
| -42.6% | -81.1% | -68.9% | -39.7% | |
| -53.2% | -110.6% | -93.2% | -50.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -98 | -102 | -61 | -100 | |
| 48 | 8 | 0 | 3 | |
| -146 | -110 | -61 | -103 | |
| Dividends paid | – | – | – | – |
| 47 | 14 | 0 | 14 | |
| 11 | 9 | 5 | 6 |
Valuation
- –
- –
- –
- 0.8×
- 5.9×
- –
- –
- -134.0%
- -161.0%
- 0.0%
Profitability
- 49.3%
- -936.1%
- -946.2%
- -843.8%
- -66.2%
- -67.2%
- -67.7%
- -57.1%
- -66.2%
- 314.8%
Growth
- +29.9%
- –
- −69.1%
- –
- +1,008.9%
Financial health
- -1.7×
- 0.01
- 0.5%
- –
- 6.99
- 6.86
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 948
Top 19%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -2.93 | -2.54 | −15.4% |
| Mar 12, 2026 | -3.98 | -3.16 | −25.9% |
| Nov 10, 2025 | -3.59 | -3.59 | +0.0% |
| Aug 11, 2025 | -3.86 | -3.10 | −24.5% |
| May 12, 2025 | -2.84 | -3.23 | +12.1% |
| Mar 18, 2025 | -9.77 | -6.23 | −56.8% |
| Nov 12, 2024 | -23.00 | -203.00 | +88.7% |
| Aug 16, 2024 | -1,928.00 | -991.00 | −94.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
75Pass
Philip Fisher
57No pass
Peter Lynch
100Pass
Joel Greenblatt
0No pass
Charlie Munger
51No pass
Terry Smith
49No pass
Questions about Tonix Pharmaceuticals
Is Tonix Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tonix Pharmaceuticals AI analysis
What does Tonix Pharmaceuticals do?
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. It is in Biotechnology.
Does Tonix Pharmaceuticals pay a dividend?
No. Tonix Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $13.8 million to shareholders by buying back its own shares.
Is Tonix Pharmaceuticals stock halal?
No. Tonix Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 270% of its market value, at or above the 33% limit. How we check
How has Tonix Pharmaceuticals stock done over the past year?
Down 73.6% over the past twelve months, to $4.49. It traded between $4.49 and $19.89 and is 77.4% below its high.
Who are Tonix Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Tonix Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.